Biomea Fusion Announces Late-Breaker Oral Presentation Showing New Analysis From The Escalation Portion Of COVALENT-111 Presented At The 1st Annual Asian Conference On Innovative Therapies For Diabetes Management; Icovamenib Achieves A Mean Reduction...

Benzinga · Nov 18 08:21

Biomea Fusion Announces Late-Breaker Oral Presentation Showing New Analysis From The Escalation Portion Of COVALENT-111 Presented At The 1st Annual Asian Conference On Innovative Therapies For Diabetes Management; Icovamenib Achieves A Mean Reduction In HbA1c Greater Than 1% At Week 26 Following 4 Weeks Of Dosing In Type 2 Diabetes Patients Characterized By Insulin Deficiency

Icovamenib Achieves a Mean Reduction in HbA1c Greater than 1% at Week 26 Following 4 Weeks of Dosing in Type 2 Diabetes Patients Characterized by Insulin Deficiency

32 patients from the 100mg and 200mg cohorts, doses selected for the expansion phase, were characterized based on baseline biomarkers and analyzed for efficacy. Patients identified as insulin deficient (approx. 50% of the broader patient population) and insulin resistant were compared to examine the mean reduction in HbA1c at Week 26, following 4 weeks of dosing.
83% of patients with insulin deficiency responded to icovamenib, and showed a greater mean HbA1c reduction at Week 26 compared to baseline, than those that were found to be more insulin resistant (-1.23% vs -0.48%, placebo-adjusted, 22 weeks after last dose of icovamenib).
These two patient groups are pre-specified in the upcoming read out of the Phase IIb expansion portion of COVALENT-111 in December, reporting over 200 persons with type 2 diabetes (T2D) with 8 and 12 weeks of icovamenib treatment.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more

Biomea Fusion Announces Late-Breaker Oral Presentation Showing New Analysis From The Escalation Portion Of COVALENT-111 Presented At The 1st Annual Asian Conference On Innovative Therapies For Diabetes Management; Icovamenib Achieves A Mean Reduction...

Risk Disclaimer